High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up

IntroductionTo evaluate the oncological outcome of high dose rate (HDR) brachytherapy (BRT) as monotherapy for clinically localised prostate cancer (PCA).Material and MethodsBetween January 2002 and February 2004, 141 consecutive patients with clinically localised PCA were treated with HDR-BRT monot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Manuel Behmueller, Nikolaos Tselis, Nikolaos Zamboglou, Eleni Zoga, Dimos Baltas, Claus Rödel, Georgios Chatzikonstantinou
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
prostate cancer
HDR-brachytherapy
monotherapy
biochemical relapse free survival
toxicity
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/9f20e301b57742689d604aec39540fa2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/9f20e301b57742689d604aec39540fa2

Ejemplares similares